메뉴 건너뛰기




Volumn 80, Issue 1, 2009, Pages 18-24

Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen

Author keywords

Combined oral contraceptives; Drospirenone; Ethinylestradiol; Pearl Index

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL;

EID: 67349145291     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.01.016     Document Type: Article
Times cited : (28)

References (34)
  • 2
    • 35348984852 scopus 로고    scopus 로고
    • Contraceptive efficacy
    • Hatcher R.A., Trussell J., Nelson A.L., Cates W., Stewart F.H., and Kowal D. (Eds), Ardent Media, New York (NY)
    • Trussell J. Contraceptive efficacy. In: Hatcher R.A., Trussell J., Nelson A.L., Cates W., Stewart F.H., and Kowal D. (Eds). Contraceptive Technology: Nineteenth Revised Edition (2007), Ardent Media, New York (NY) 747-826
    • (2007) Contraceptive Technology: Nineteenth Revised Edition , pp. 747-826
    • Trussell, J.1
  • 3
    • 0033833321 scopus 로고    scopus 로고
    • Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
    • Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-38
    • (2000) Contraception , vol.62 , pp. 29-38
    • Krattenmacher, R.1
  • 4
    • 0028910917 scopus 로고
    • Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models
    • Muhn P., Krattenmacher R., Beier S., Elger W., and Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 51 (1995) 99-110
    • (1995) Contraception , vol.51 , pp. 99-110
    • Muhn, P.1    Krattenmacher, R.2    Beier, S.3    Elger, W.4    Schillinger, E.5
  • 5
    • 0030273673 scopus 로고    scopus 로고
    • The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential
    • Fuhrmann U., Krattenmacher R., Slater E.P., and Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 (1996) 243-251
    • (1996) Contraception , vol.54 , pp. 243-251
    • Fuhrmann, U.1    Krattenmacher, R.2    Slater, E.P.3    Fritzemeier, K.H.4
  • 6
    • 34047263992 scopus 로고    scopus 로고
    • The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation
    • Dinger J.C., Heinemann L.A., and Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
    • (2007) Contraception , vol.75 , pp. 344-354
    • Dinger, J.C.1    Heinemann, L.A.2    Kuhl-Habich, D.3
  • 7
    • 0000275817 scopus 로고    scopus 로고
    • A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel
    • Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., and Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5 (2000) 124-134
    • (2000) Eur J Contracept Reprod Health Care , vol.5 , pp. 124-134
    • Foidart, J.M.1    Wuttke, W.2    Bouw, G.M.3    Gerlinger, C.4    Heithecker, R.5
  • 8
    • 0034113938 scopus 로고    scopus 로고
    • Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone
    • Huber J., Foidart J.M., Wuttke W., et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 5 (2000) 25-34
    • (2000) Eur J Contracept Reprod Health Care , vol.5 , pp. 25-34
    • Huber, J.1    Foidart, J.M.2    Wuttke, W.3
  • 9
    • 0034058861 scopus 로고    scopus 로고
    • An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen
    • Parsey K.S., and Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61 (2000) 105-111
    • (2000) Contraception , vol.61 , pp. 105-111
    • Parsey, K.S.1    Pong, A.2
  • 10
    • 0037327909 scopus 로고    scopus 로고
    • Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life
    • Borenstein J., Yu H.T., Wade S., Chiou C.F., and Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 48 (2003) 79-85
    • (2003) J Reprod Med , vol.48 , pp. 79-85
    • Borenstein, J.1    Yu, H.T.2    Wade, S.3    Chiou, C.F.4    Rapkin, A.5
  • 11
    • 33846840621 scopus 로고    scopus 로고
    • The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study
    • Fruzzetti F., Lello S., Lazzarini V., et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 75 (2007) 199-203
    • (2007) Contraception , vol.75 , pp. 199-203
    • Fruzzetti, F.1    Lello, S.2    Lazzarini, V.3
  • 12
    • 0037355597 scopus 로고    scopus 로고
    • Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms
    • Apter D., Borsos A., Baumgartner W., et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8 (2003) 37-51
    • (2003) Eur J Contracept Reprod Health Care , vol.8 , pp. 37-51
    • Apter, D.1    Borsos, A.2    Baumgartner, W.3
  • 13
    • 33845981485 scopus 로고    scopus 로고
    • Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception
    • Borges L.E., Andrade R.P., Aldrighi J.M., et al. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception 74 (2006) 446-450
    • (2006) Contraception , vol.74 , pp. 446-450
    • Borges, L.E.1    Andrade, R.P.2    Aldrighi, J.M.3
  • 14
    • 0034471461 scopus 로고    scopus 로고
    • The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being
    • Boschitsch E., Skarabis H., Wuttke W., and Heithecker R. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 5 Suppl 3 (2000) 34-40
    • (2000) Eur J Contracept Reprod Health Care , vol.5 , Issue.SUPPL. 3 , pp. 34-40
    • Boschitsch, E.1    Skarabis, H.2    Wuttke, W.3    Heithecker, R.4
  • 15
    • 4344565828 scopus 로고    scopus 로고
    • Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone
    • Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., and Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 70 (2004) 191-198
    • (2004) Contraception , vol.70 , pp. 191-198
    • Bachmann, G.1    Sulak, P.J.2    Sampson-Landers, C.3    Benda, N.4    Marr, J.5
  • 16
    • 19444379341 scopus 로고    scopus 로고
    • Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
    • Klipping C., and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71 (2005) 409-416
    • (2005) Contraception , vol.71 , pp. 409-416
    • Klipping, C.1    Marr, J.2
  • 17
    • 27944495205 scopus 로고    scopus 로고
    • Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation
    • Pearlstein T.B., Bachmann G.A., Zacur H.A., and Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
    • (2005) Contraception , vol.72 , pp. 414-421
    • Pearlstein, T.B.1    Bachmann, G.A.2    Zacur, H.A.3    Yonkers, K.A.4
  • 18
    • 23944510662 scopus 로고    scopus 로고
    • Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder
    • Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., and Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
    • (2005) Obstet Gynecol , vol.106 , pp. 492-501
    • Yonkers, K.A.1    Brown, C.2    Pearlstein, T.B.3    Foegh, M.4    Sampson-Landers, C.5    Rapkin, A.6
  • 19
    • 34547871600 scopus 로고    scopus 로고
    • Drospirenone/ethinylestradiol 3 mg/20 μg (24/4 day regimen)
    • Fenton C., Wellington K., Moen M.D., and Robinson D.M. Drospirenone/ethinylestradiol 3 mg/20 μg (24/4 day regimen). Drugs 67 (2007) 1749-1765
    • (2007) Drugs , vol.67 , pp. 1749-1765
    • Fenton, C.1    Wellington, K.2    Moen, M.D.3    Robinson, D.M.4
  • 20
    • 0031856274 scopus 로고    scopus 로고
    • An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive
    • The Mircette Study Group
    • The Mircette Study Group. An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. Am J Obstet Gynecol 179 (1998) S2-S8
    • (1998) Am J Obstet Gynecol , vol.179
  • 21
    • 0032755922 scopus 로고    scopus 로고
    • Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG)
    • Archer D.F., Maheux R., DelConte A., and O'Brien F.B. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 181 5 Pt 2 (1999) 39-44
    • (1999) Am J Obstet Gynecol , vol.181 , Issue.5 PART 2 , pp. 39-44
    • Archer, D.F.1    Maheux, R.2    DelConte, A.3    O'Brien, F.B.4
  • 22
    • 0033009406 scopus 로고    scopus 로고
    • International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg
    • Boerrigter P.J., Ellman H., and Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg. Clin Ther 21 (1999) 118-127
    • (1999) Clin Ther , vol.21 , pp. 118-127
    • Boerrigter, P.J.1    Ellman, H.2    Dolker, M.3
  • 23
    • 0343765846 scopus 로고    scopus 로고
    • A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance
    • Endrikat J., Muller U., and Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 55 (1997) 131-137
    • (1997) Contraception , vol.55 , pp. 131-137
    • Endrikat, J.1    Muller, U.2    Dusterberg, B.3
  • 24
    • 0033063642 scopus 로고    scopus 로고
    • Large observational trial of a new low-dose oral contraceptive containing 20 micrograms ethinylestradiol and 100 micrograms levonorgestrel (Miranova) in Germany
    • Hite R.C., Bannemerschult R., Fox-Kuchenbecker P., Turck R., and Brill K. Large observational trial of a new low-dose oral contraceptive containing 20 micrograms ethinylestradiol and 100 micrograms levonorgestrel (Miranova) in Germany. Eur J Contracept Reprod Health Care 4 (1999) 7-13
    • (1999) Eur J Contracept Reprod Health Care , vol.4 , pp. 7-13
    • Hite, R.C.1    Bannemerschult, R.2    Fox-Kuchenbecker, P.3    Turck, R.4    Brill, K.5
  • 25
    • 33749302110 scopus 로고    scopus 로고
    • Oral contraceptive use and protective behavior after missed pills
    • Oakley D, Potter L, de Leon-Wong E, Visness C. Oral contraceptive use and protective behavior after missed pills. Fam Plann Perspect 1997;29:277-9, 287.
    • (1997) Fam Plann Perspect , vol.29 , Issue.277-279 , pp. 287
    • Oakley, D.1    Potter, L.2    de Leon-Wong, E.3    Visness, C.4
  • 27
    • 33745585200 scopus 로고    scopus 로고
    • Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg
    • Cibula D., Karck U., Weidenhammer H.G., Kunz J., Alincic S., and Marr J. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg. Clin Drug Investig 26 (2006) 143-150
    • (2006) Clin Drug Investig , vol.26 , pp. 143-150
    • Cibula, D.1    Karck, U.2    Weidenhammer, H.G.3    Kunz, J.4    Alincic, S.5    Marr, J.6
  • 29
    • 0033168809 scopus 로고    scopus 로고
    • Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity
    • Sullivan H., Furniss H., Spona J., and Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 72 (1999) 115-120
    • (1999) Fertil Steril , vol.72 , pp. 115-120
    • Sullivan, H.1    Furniss, H.2    Spona, J.3    Elstein, M.4
  • 30
    • 0030222154 scopus 로고    scopus 로고
    • Shorter pill-free interval in combined oral contraceptives decreases follicular development
    • Spona J., Elstein M., Feichtinger W., et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54 (1996) 71-77
    • (1996) Contraception , vol.54 , pp. 71-77
    • Spona, J.1    Elstein, M.2    Feichtinger, W.3
  • 31
    • 33745947094 scopus 로고    scopus 로고
    • Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval
    • Willis S.A., Kuehl T.J., Spiekerman A.M., and Sulak P.J. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74 (2006) 100-103
    • (2006) Contraception , vol.74 , pp. 100-103
    • Willis, S.A.1    Kuehl, T.J.2    Spiekerman, A.M.3    Sulak, P.J.4
  • 32
    • 44949121513 scopus 로고    scopus 로고
    • Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen
    • Klipping C., Duijkers I., Trummer D., and Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 78 (2008) 16-25
    • (2008) Contraception , vol.78 , pp. 16-25
    • Klipping, C.1    Duijkers, I.2    Trummer, D.3    Marr, J.4
  • 33
    • 15744363767 scopus 로고    scopus 로고
    • Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations
    • Mishell Jr. D.R. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception 71 (2005) 304-305
    • (2005) Contraception , vol.71 , pp. 304-305
    • Mishell Jr., D.R.1
  • 34
    • 40649128938 scopus 로고    scopus 로고
    • Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial
    • Koltun W., Lucky A.W., Thiboutot D., et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 77 (2008) 249-256
    • (2008) Contraception , vol.77 , pp. 249-256
    • Koltun, W.1    Lucky, A.W.2    Thiboutot, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.